-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From July 2nd to 3rd, the Fifth Aerospace Blood Annual Conference and National Continuing Education Project-Relapsed and Refractory Leukemia and Lymphoma Treatment Workshop was held in Beijing
.
"Technical innovation is the foundation of disciplinary progress, but firm belief, persistent pursuit, and down-to-earth are the necessary conditions for achievement
.
Professor Wang Jingbo's hard work in the field of blood diseases is the practice and confirmation of this
.
Today we not only need to conduct academic studies.
It is even more important to learn these excellent qualities
.
Only in this way can we achieve transcendence, and generations of new forces can achieve continuous innovation and progress
.
"Professor Huang Xiaojun from the Institute of Hematology, Peking University said at the opening ceremony held on July 3.
Hope for the development of hematology
.
"It is the responsibility of doctors to save lives
.
The content of this conference is comprehensive and detailed, covering all aspects of clinical diagnosis and treatment of relapsed and refractory leukemia and basic research.
I believe the participants will gain a lot
.
" Professor Han Mingzhe, Hospital of Hematology, Chinese Academy of Medical Sciences Said
.
"The Department of Hematology, Aerospace Center Hospital, under the leadership of Director Wang Jingbo, has become an important new force in the diagnosis and treatment of relapsed and refractory leukemia in China.
I believe that more and better results will be made in the future
.
" said Professor Wu Depei, the First Affiliated Hospital of Soochow University
.
"I believe this academic exchange will help us improve our understanding and treatment of relapsed and refractory leukemia, thereby shortening the distance of the last mile and promoting the progress of the discipline!" said Professor Wang Jianxiang, Hospital of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences
.
"In 2012, the Department of Hematology of the Aerospace Center Hospital was established.
In the past 9 years, it has grown from nothing, from weak to strong
.
At present, the department of hematology has nearly a hundred beds and completed more than 1,100 stem cell transplants.
The department of hematology has become a resounding hospital.
card
.
I hope this meeting can optimize blood disease treatment system, promote the transformation of clinical blood diseases cutting-edge technology, and ultimately benefit more patients with hematological disorders
.
"space Center hospital, vice president Li to express
.
The opening ceremony was presided over by Professor Wang Jingbo, the chairman of the conference and the director of the Department of Hematology of the Aerospace Center Hospital.
Professor Wang introduced that this conference has four highlights: First, take root in the clinic and share experience with many practical problems encountered in clinical practice; 2.
The organic combination of basic science and clinical practice.
The conference invites experts in basic fields such as immunology and stem cell science to give lectures, answering clinical questions with a "basic" perspective; third, covering every corner of the field of hemolymphoma, from children to the elderly The content is comprehensive, ranging from chemotherapy, targeted therapy to stem cell transplantation and post-transplantation complications.
Fourth, hematology experts from 25 provinces (regions) and cities across the country participate in lectures and share clinical practice experience in hematology in each region , To bring an academic feast to the participants
.
The chairman of the conference interviewed Professor Wang Jingbo, director of the Department of Hematology of the Aerospace Center Hospital, to do a good job in the test field.
Every patient has hope.
"Patients who do not remission cannot be transplanted" is the curse of leukemia patients in the choice of treatment methods.
Many patients do not have organ damage or drug resistance.
Bacterial infections and other difficult problems are not alleviated, thus losing the opportunity to extend the survival period through stem cell transplantation
.
However, in December 2006, this curse was broken
.
Professor Wang Jingbo completed the first case of stem cell transplantation for a non-remission patient.
It is a young girl who recently sent her a photo and is recovering well
.
Patients who do not remission can also be transplanted.
In 1981, China initiated hematopoietic stem cell transplantation to treat leukemia, but at that time it was believed that transplantation could only be carried out in remission
.
The so-called remission means that there are no leukemia cells in the peripheral blood of the patient, and the leukemia cells in the bone marrow are less than 5%
.
Professor Wang Jingbo introduced that 20% to 30% of leukemia patients cannot achieve remission.
When hematopoietic stem cell transplantation is first carried out, remission is a hard target
.
In 2006, following the successful transplantation of the first non-remission patient, the life of the non-remission patient ushered in the dawn of life
.
At present, among non-remission patients, 40% of myeloid leukemia patients and 25% to 30% of lymphoid leukemia patients can achieve long-term survival through hematopoietic stem cell transplantation
.
Two three major characteristics of relapsed and refractory leukemia Patients with relapsed and refractory leukemia often have undergone repeated chemotherapy and targeted therapy.
This hospital does not relieve after treatment.
Try another one, and the repeated "battles" have caused it.
Many undesirable consequences
.
According to Professor Wang Jingbo, such patients often have three major characteristics: First, repeated blows damage various organs of the body, resulting in poor organ function; second, the lack of granulocytes after each chemotherapy is easy to cause infection, and they are treated with antibiotics repeatedly.
In the case of infection, there will be an increase in drug-resistant bacteria in the body; thirdly, the reason for not alleviating is mainly because the leukemia cells in the body have deteriorated strongly.
This is not just a problem of cell growth, but a change in function.
The production of many cytokines causes damage to normal tissues and organs.
In many interstitial spaces, including subcutaneous, mediastinum, retroperitoneum, intracranial, and bone marrow, there will be infiltration of leukemia cells.
In this way, patients are more difficult to treat
.
3.
"Private customization" to improve the prognosis of patients.
"If leukemia cells are compared to enemies, for patients who are relieved after treatment, the leukemia cells in their bodies are equivalent to the enemy holding a submachine gun to fight, then we may be able to deal with it with a cannon ; For patients who are not in remission, the leukemia cells may have come in an airplane, so more powerful weapons, such as missiles, are needed
.
” Professor Wang Jingbo vividly compared the confrontation with leukemia cells to a battle.
The “missile” is What? The first is the improvement and strengthening of treatment strategies, and individualized and customized pretreatment programs are carried out according to the different characteristics of each person; second, for the improvement of transplants, in addition to the donor's hematopoietic stem cells, third-party cord blood can be considered Stem cells; third, improve relevant inspections, monitor leukemia cells, understand their characteristics, and select donors scientifically; fourth, effective maintenance after transplantation is also crucial, including multi-directional monitoring of leukemia cells, immunosuppressive agents Reasonable dose reduction, immunotherapy, targeted drug therapy, epigenetic drug therapy (including demethylation drugs and histone deacetylase inhibitors, etc.
)
.
Establishing a reproducible scientific system "The treatment of relapsed and refractory leukemia is still at the preliminary stage of exploration
.
" Professor Wang Jingbo pointedly pointed out that due to the highly individualized treatment of relapsed and refractory leukemia, there has not yet been a complete and scientific treatment.
。The system .
Although there are some consensuses, they are not fully applicable to clinical practice
.
"What we need is a successful system that can be replicated across the country.
This requires more evidence-based medicine and the accumulation of clinical cases
.
" Professor Wang Jingbo said that despite the difficult exploration, we finally saw the light
.
For the future, Professor Wang Jingbo is full of hope: "First, we must build a trial field, accumulate clinical experience, establish a scientific diagnosis and treatment system, and promote it to the whole country to benefit more patients; second, let more doctors and patients know, Patients who are not in remission can also be transplanted.
Every patient has hope!” END Typesetting: Hu Haiyan Editor: Jia Weiwei Review: Xu Fengyan For more content, please click: Witnessing the glory of a hundred years is the glory of prosperity | At the celebration of the centennial of the founding of the party, I I escaped a catastrophe while watching the ceremony in front of Tiananmen Square.
Will I be so lucky next time? "Physician Daily" submission public email: yishibao2017@163.
com [Note] Some pictures are from the Internet and WeChat Moments.
If there is any infringement, please contact to delete, thank you! Tel: 010-58302828-6808 Currently 1130000+ doctors have been following to join us
.
"Technical innovation is the foundation of disciplinary progress, but firm belief, persistent pursuit, and down-to-earth are the necessary conditions for achievement
.
Professor Wang Jingbo's hard work in the field of blood diseases is the practice and confirmation of this
.
Today we not only need to conduct academic studies.
It is even more important to learn these excellent qualities
.
Only in this way can we achieve transcendence, and generations of new forces can achieve continuous innovation and progress
.
"Professor Huang Xiaojun from the Institute of Hematology, Peking University said at the opening ceremony held on July 3.
Hope for the development of hematology
.
"It is the responsibility of doctors to save lives
.
The content of this conference is comprehensive and detailed, covering all aspects of clinical diagnosis and treatment of relapsed and refractory leukemia and basic research.
I believe the participants will gain a lot
.
" Professor Han Mingzhe, Hospital of Hematology, Chinese Academy of Medical Sciences Said
.
"The Department of Hematology, Aerospace Center Hospital, under the leadership of Director Wang Jingbo, has become an important new force in the diagnosis and treatment of relapsed and refractory leukemia in China.
I believe that more and better results will be made in the future
.
" said Professor Wu Depei, the First Affiliated Hospital of Soochow University
.
"I believe this academic exchange will help us improve our understanding and treatment of relapsed and refractory leukemia, thereby shortening the distance of the last mile and promoting the progress of the discipline!" said Professor Wang Jianxiang, Hospital of Hematology, Institute of Hematology, Chinese Academy of Medical Sciences
.
"In 2012, the Department of Hematology of the Aerospace Center Hospital was established.
In the past 9 years, it has grown from nothing, from weak to strong
.
At present, the department of hematology has nearly a hundred beds and completed more than 1,100 stem cell transplants.
The department of hematology has become a resounding hospital.
card
.
I hope this meeting can optimize blood disease treatment system, promote the transformation of clinical blood diseases cutting-edge technology, and ultimately benefit more patients with hematological disorders
.
"space Center hospital, vice president Li to express
.
The opening ceremony was presided over by Professor Wang Jingbo, the chairman of the conference and the director of the Department of Hematology of the Aerospace Center Hospital.
Professor Wang introduced that this conference has four highlights: First, take root in the clinic and share experience with many practical problems encountered in clinical practice; 2.
The organic combination of basic science and clinical practice.
The conference invites experts in basic fields such as immunology and stem cell science to give lectures, answering clinical questions with a "basic" perspective; third, covering every corner of the field of hemolymphoma, from children to the elderly The content is comprehensive, ranging from chemotherapy, targeted therapy to stem cell transplantation and post-transplantation complications.
Fourth, hematology experts from 25 provinces (regions) and cities across the country participate in lectures and share clinical practice experience in hematology in each region , To bring an academic feast to the participants
.
The chairman of the conference interviewed Professor Wang Jingbo, director of the Department of Hematology of the Aerospace Center Hospital, to do a good job in the test field.
Every patient has hope.
"Patients who do not remission cannot be transplanted" is the curse of leukemia patients in the choice of treatment methods.
Many patients do not have organ damage or drug resistance.
Bacterial infections and other difficult problems are not alleviated, thus losing the opportunity to extend the survival period through stem cell transplantation
.
However, in December 2006, this curse was broken
.
Professor Wang Jingbo completed the first case of stem cell transplantation for a non-remission patient.
It is a young girl who recently sent her a photo and is recovering well
.
Patients who do not remission can also be transplanted.
In 1981, China initiated hematopoietic stem cell transplantation to treat leukemia, but at that time it was believed that transplantation could only be carried out in remission
.
The so-called remission means that there are no leukemia cells in the peripheral blood of the patient, and the leukemia cells in the bone marrow are less than 5%
.
Professor Wang Jingbo introduced that 20% to 30% of leukemia patients cannot achieve remission.
When hematopoietic stem cell transplantation is first carried out, remission is a hard target
.
In 2006, following the successful transplantation of the first non-remission patient, the life of the non-remission patient ushered in the dawn of life
.
At present, among non-remission patients, 40% of myeloid leukemia patients and 25% to 30% of lymphoid leukemia patients can achieve long-term survival through hematopoietic stem cell transplantation
.
Two three major characteristics of relapsed and refractory leukemia Patients with relapsed and refractory leukemia often have undergone repeated chemotherapy and targeted therapy.
This hospital does not relieve after treatment.
Try another one, and the repeated "battles" have caused it.
Many undesirable consequences
.
According to Professor Wang Jingbo, such patients often have three major characteristics: First, repeated blows damage various organs of the body, resulting in poor organ function; second, the lack of granulocytes after each chemotherapy is easy to cause infection, and they are treated with antibiotics repeatedly.
In the case of infection, there will be an increase in drug-resistant bacteria in the body; thirdly, the reason for not alleviating is mainly because the leukemia cells in the body have deteriorated strongly.
This is not just a problem of cell growth, but a change in function.
The production of many cytokines causes damage to normal tissues and organs.
In many interstitial spaces, including subcutaneous, mediastinum, retroperitoneum, intracranial, and bone marrow, there will be infiltration of leukemia cells.
In this way, patients are more difficult to treat
.
3.
"Private customization" to improve the prognosis of patients.
"If leukemia cells are compared to enemies, for patients who are relieved after treatment, the leukemia cells in their bodies are equivalent to the enemy holding a submachine gun to fight, then we may be able to deal with it with a cannon ; For patients who are not in remission, the leukemia cells may have come in an airplane, so more powerful weapons, such as missiles, are needed
.
” Professor Wang Jingbo vividly compared the confrontation with leukemia cells to a battle.
The “missile” is What? The first is the improvement and strengthening of treatment strategies, and individualized and customized pretreatment programs are carried out according to the different characteristics of each person; second, for the improvement of transplants, in addition to the donor's hematopoietic stem cells, third-party cord blood can be considered Stem cells; third, improve relevant inspections, monitor leukemia cells, understand their characteristics, and select donors scientifically; fourth, effective maintenance after transplantation is also crucial, including multi-directional monitoring of leukemia cells, immunosuppressive agents Reasonable dose reduction, immunotherapy, targeted drug therapy, epigenetic drug therapy (including demethylation drugs and histone deacetylase inhibitors, etc.
)
.
Establishing a reproducible scientific system "The treatment of relapsed and refractory leukemia is still at the preliminary stage of exploration
.
" Professor Wang Jingbo pointedly pointed out that due to the highly individualized treatment of relapsed and refractory leukemia, there has not yet been a complete and scientific treatment.
。The system .
Although there are some consensuses, they are not fully applicable to clinical practice
.
"What we need is a successful system that can be replicated across the country.
This requires more evidence-based medicine and the accumulation of clinical cases
.
" Professor Wang Jingbo said that despite the difficult exploration, we finally saw the light
.
For the future, Professor Wang Jingbo is full of hope: "First, we must build a trial field, accumulate clinical experience, establish a scientific diagnosis and treatment system, and promote it to the whole country to benefit more patients; second, let more doctors and patients know, Patients who are not in remission can also be transplanted.
Every patient has hope!” END Typesetting: Hu Haiyan Editor: Jia Weiwei Review: Xu Fengyan For more content, please click: Witnessing the glory of a hundred years is the glory of prosperity | At the celebration of the centennial of the founding of the party, I I escaped a catastrophe while watching the ceremony in front of Tiananmen Square.
Will I be so lucky next time? "Physician Daily" submission public email: yishibao2017@163.
com [Note] Some pictures are from the Internet and WeChat Moments.
If there is any infringement, please contact to delete, thank you! Tel: 010-58302828-6808 Currently 1130000+ doctors have been following to join us
